Inclusion Criteria:

• Karnofsky Performance Status (KPS) > 70%.
• Expected Survival > 3 months.
• Advanced or metastatic, histologically or cytologically documented solid tumors, lymphomas, for which there is no available therapy shown to provide clinical benefit.
• Adequate renal, liver, pancreatic and hematological function
• Signed informed consent
• Mentally competent. Ability to understand and willingness to sign the informed consent form.
• Willingness to practice birth control

Exclusion Criteria:

• Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 4 weeks prior to initiation of CPI-613.
• Patients with an active tumor of the central nervous system ( CNS) or epidural tumor
• Patients with active heart disease including myocardial infarction within previous 6 months, symptomatic coronary artery disease, arrhythmias requiring medication, or symptomatic congestive heart failure.
• History of risk factors for Torsades de Pointes ( heart failure, hypokalemia, family history of Long QT Syndrome
• Patients with a marked baseline QT/QTc interval > 450ms (e.g., heart failure, hypokalemia, and family history of Long QT Syndrome).
• Serious medical illness such as significant cardiac disease ( Symptomatic CHF, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or New York Heart Association Class III or IV, or severe debilitating pulmonary disease that would potentially increase the patients risk for developing toxicityTroponin I >0.05ng/mL or Left Ventricular Ejection Fraction ( LVEF) below 35%
• Dyspnea with mild exertion
• Pregnant or breast-feeding women.
• Concurrent, active secondary malignancy for which the patient is receiving therapy.
• Requirement for immediate palliative treatment of any kind including surgery.
• Patients who have received immunotherapy in the past 4 weeks prior to initiation of CPI-613
• Patients who are known to be HIV positive